Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The clinical activity and side effects of a new phenyl acetic-acid derivative, diclofenac, have been assessed in 24 patients with rheumatoid disease. Diclofenac 25 mg q.i.d. was compared with 750mg of aspirin BP q.i.d. using a double-blind crossover technique involving four weeks on each drug. Benefits were similar for the two preparations but with improvement in morning stiffness and incidence of dyspepsia favouring diclofenac, and a more marked reduction of the sedimentation rate occurring with aspirin. A moderate elevation of liver enzymes was seen in one patient on diclofenac, and of lactate dehydrogenase in one other. It is concluded that diclofenac is a therapeutically active analgesic anti-inflammatory agent.
 ...
PMID:Diclofenac in rheumatoid disease. 37 67

A double-blind trial compared diclofenac with placebo in 44 outpatients. On from each group dropped out with dyspepsia, and one (placebo group) with ineffective treatment. Twenty completers received diclofenac. Dosage was one tablet (25 mg diclofenac) three times daily during the first week. In the second (final) week, most patients had four or six tablets. Diclofenac had significantly greater effect on pain, grip, morning stiffness, joint tenderness and swelling, and in comparison to previous treatments, even though the placebo group required significantly more rescue anaglesic. A few patients in each group had slight dyspepsia. One in the active and six in the placebo group complained of minor central nervous system symptoms. There were no serious side-effects. Haematological, biochemical and urinary analyses showed no clinically important changes. It is concluded that, in the short term, diclofenac (Voltarol) is effective in relieving the symptoms of inflammatory polyarthritis. It is well tolerated as placebo medication, and had no detrimental haematological or biochemical effects.
 ...
PMID:Diclofenac (Voltarol) in rheumatoid arthritis: a report of a double-blind trial. 39 80

46 patients with rheumatic diseases suffering from dyspepsia and endoscopically proven gastroduodenal lesions entered a double-blind placebo-controlled study with ranitidine 150 mg b.i.d. over 4-8 weeks. The patients had to be treated for at least 3 months with the non-steroidal antiinflammatory drugs (NSAID) Diclofenac, Indomethacin, and Piroxicam before entering the study. During the trial all patients had to continue on NSAID. At entry patients in the placebo group (n = 23) had a total number of 33 gastrointestinal lesions of grade 1-3. In the ranitidine group (n = 23) a total number of 28 gastrointestinal lesions had been counted. After 4 weeks of treatment the number of lesions had been reduced in the placebo group to 20 and in the ranitidine group to 6 (p less than 0.05). The total damaging score at entry averaging 2.0 under placebo and 1.0 under ranitidine had been reduced to 1.3 (placebo) and 0.3 (ranitidine). (p less than 0.05). Our results underline the efficacy of ranitidine in the treatment of NSAID-induced gastroduodenal mucosal lesions.
 ...
PMID:[Ranitidine in the treatment of non-steroidal anti-inflammatory agent-induced damage of the stomach and duodenal mucosa. Results of a randomized, placebo-controlled double-blind study in patients with rheumatic diseases]. 306 Nov 83